Allakos Inc. logo

Allakos Inc.

NASDAQ:ALLK

Overview | Financials
Company Name Allakos Inc.
Symbol ALLK
Currency USD
Price 0.54
Market Cap 47,979,378
Dividend Yield 0%
52-week-range 0.54 - 3.41
Industry Biotechnology
Sector Healthcare
CEO Dr. Robert Alexander Ph.D.
Website https://www.allakos.com

An error occurred while fetching data.

About Allakos Inc.

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase

Related Stocks

Meihua International Medical Technologies Co., Ltd. logo

Meihua International Medical Technologies Co., Ltd.

MHUA

1.03 USD

Sensus Healthcare, Inc. logo

Sensus Healthcare, Inc.

SRTS

6.07 USD

TFF Pharmaceuticals, Inc. logo

TFF Pharmaceuticals, Inc.

TFFP

2.28 USD

Vor Biopharma Inc. logo

Vor Biopharma Inc.

VOR

0.934 USD

Quipt Home Medical Corp. logo

Quipt Home Medical Corp.

QIPT

2.88 USD

Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc.

ABOS

2.44 USD

scPharmaceuticals Inc. logo

scPharmaceuticals Inc.

SCPH

5.43 USD

NeuroPace, Inc. logo

NeuroPace, Inc.

NPCE

6.82 USD

Financials

Numbers are in millions USD

Numbers are in millions USD